SEC Form 4 · accession 0001209191-17-019098
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Mar 3, 2017
Accepted (ET)
Mar 7, 2017 · 8:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 3, 2017 | M | 4,710 | $23.31 | A | 82,946 | D | |
| Common StockF2,F3,F4,F1 | Mar 3, 2017 | S | 4,710 | $31.0914 | D | 78,236 | D | |
| Common StockF1 | Mar 6, 2017 | M | 290 | $23.31 | A | 78,526 | D | |
| Common StockF2,F3,F5,F1 | Mar 6, 2017 | S | 290 | $31.0838 | D | 78,236 | D | |
| Common Stock | holding | — | — | — | 12,298 | I | Held by UBS for Benefit of Kimberly Popovits | |
| Common Stock | holding | — | — | — | 16,825 | I | Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee. | |
| Common Stock | holding | — | — | — | 200,851 | I | Held by the Popovits 2010 Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $23.31 | Mar 3, 2017 | M | 4,710 | D | — | Dec 6, 2017 | Common Stock | 0 | 3,190 | D |
| Employee Stock Option (right to buy)F6 | $23.31 | Mar 6, 2017 | M | 290 | D | — | Dec 6, 2017 | Common Stock | 0 | 2,900 | D |
Explanation of responses
- F1Includes an aggregate of 45,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2016.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $30.65 to $31.22.
- F5Represents weighted average sale price. Actual sale prices ranged from $30.96 to $31.17.
- F6The option became exercisable as to 25% of the shares on December 6, 2008, and became exercisable as to 1/48th of the shares each full month thereafter.